Drug discovery and healthcare support portfolio spanning 4 businesses
First written in FY2016. 17 of 31 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The Group, comprising the Company and its affiliated companies, consists of the Company and 16 subsidiaries. Its principal activities are contract production of genetically modified mice, contract antibody production and glycan analysis and synthesis, contract clinical and nonclinical testing, contract genetic analysis, promotion of new businesses through M&A, and advisory and support services in the fields of business succession and business revitalization.」
The Group structure comprising 16 subsidiaries and a business portfolio centered on the drug discovery support and Investment and Consulting businesses has been reaffirmed. - FY2026-H1RestatedAnnual report
「There were no significant changes during the interim consolidated accounting period in the main businesses operated by the Group, comprising the Company and its affiliated companies. There were also no changes among the principal affiliated companies.」
It has been reaffirmed that there were no significant changes to the business portfolio centered on the drug discovery support business and the Investment and Consulting business, or to the principal affiliated companies. - FY2025ReframedAnnual report
「The Group, comprising the Company and its affiliated companies, consists of the Company and 16 subsidiaries,」
Following the absorption-type merger of 安評センター by 新薬リサーチセンター and the conversion of 東北新和化学 into a subsidiary, the Group structure changed from 17 companies in the previous interim period to 16. The reporting segments have been maintained as the two segments of drug discovery support and Investment and Consulting. - FY2025-H1AdvancedAnnual report
「As a result, as of 30 September 2024, the Group consisted of the Company and 17 consolidated subsidiaries.」
The number of consolidated subsidiaries increased by 1 to 17 following the acquisition of shares by 株式会社ＴＧビジネスサービス, which operates the Investment and Consulting business. - FY2024-Q3RestatedAnnual report
「There were no significant changes during the third quarter consolidated cumulative period in the main businesses operated by the Group, comprising the Company and its affiliated companies. There were also no changes among the principal affiliated companies.」
It has been reaffirmed that there were no significant changes to the business portfolio centered on the drug discovery support business and the Investment and Consulting business, or to the principal affiliated companies. - FY2024-Q2RestatedAnnual report
「There were no significant changes during the second quarter consolidated cumulative period in the main businesses operated by the Group, comprising the Company and its affiliated companies. There were also no changes among the principal affiliated companies.」
It has been reaffirmed that there were no significant changes to the business portfolio centered on the drug discovery support business and the Investment and Consulting business, or to the principal affiliated companies. - FY2024-Q1RestatedAnnual report
「There were no significant changes during the first quarter consolidated cumulative period in the main businesses operated by the Group, comprising the Company and its affiliated companies. There were also no changes among the principal affiliated companies.」
It has been reaffirmed that there were no significant changes to the business portfolio centered on the drug discovery support business and the Investment and Consulting business, or to the principal affiliated companies. - FY2023-Q3RestatedAnnual report
「During the second quarter consolidated accounting period, the number of consolidated subsidiaries increased by 1 as a result of the acquisition of shares by 株式会社ＴＧビジネスサービス, which operates the business described above. As a result, as of 31 December 2022, the Group consisted of the Company and 16 consolidated subsidiaries.」
Following TGBS's acquisition of shares in the second quarter, the Group structure comprising 16 consolidated subsidiaries has been reaffirmed. - FY2023-Q2AdvancedAnnual report
「During the second quarter consolidated accounting period, the number of consolidated subsidiaries increased by 1 as a result of the acquisition of shares by 株式会社ＴＧビジネスサービス, which operates the business described above. As a result, as of 30 September 2022, the Group consisted of the Company and 16 consolidated subsidiaries.」
The number of consolidated subsidiaries increased by 1 following the acquisition of shares by 株式会社ＴＧビジネスサービス, resulting in a Group structure comprising 16 consolidated subsidiaries as of 30 September 2022. - FY2023-Q1ReframedAnnual report
「Beginning with the first quarter consolidated accounting period, the name of the former segment was changed from the “TGBS business” to the “Investment and Consulting business.” This change in segment name had no effect on segment information.」
The two-segment business portfolio has been maintained, with the former TGBS business renamed the Investment and Consulting business. - FY2022-Q3AdvancedAnnual report
「During the third quarter consolidated accounting period, the Company acquired all shares of 株式会社ルナパス毒性病理研究所 and made it a subsidiary. Accordingly, the company has been newly included in the scope of consolidation. As a result, as of 31 December 2021, the Group consisted of the Company and 16 consolidated subsidiaries.」
The number of consolidated subsidiaries increased to 16 following the acquisition of 株式会社ルナパス毒性病理研究所 as a subsidiary and the acquisition of shares in the TGBS business. - FY2022-Q2AdvancedAnnual report
「As a result, as of 30 September 2021, the Group comprised the Company and 15 consolidated subsidiaries.」
Following the acquisition of shares by 株式会社ＴＧビジネスサービス, the number of consolidated subsidiaries increased by 1 to 15, expanding the Group structure. - FY2021RestatedAnnual report
「The Group, comprising the Company and 14 subsidiaries, is principally engaged in contract production of genetically modified mice and antibodies, contract clinical and nonclinical studies, contract genetic analysis, pathological diagnostic services, promotion of new businesses through M&A, and advisory and support services in business succession and business revitalization.」
This reconfirms the Group structure comprising 14 subsidiaries and the business portfolio centered on drug discovery support and TGBS. The reportable segments are presented as 2 segments: the drug discovery support and TGBS businesses. - FY2021-Q3AdvancedAnnual report
「During the three-month period ended in the second quarter, 株式会社ＴＧビジネスサービス, a subsidiary of the Company, acquired 60% of the shares in 株式会社キヅキ, and the company was newly included in the scope of consolidation. During the three-month period ended in the third quarter, an additional 40% of its shares were acquired.」
Following the initial 60% acquisition of 株式会社キヅキ through TGBS, an additional 40% was acquired. The Group continued to expand. - FY2021-Q2AdvancedAnnual report
「During the three-month period ended in the second quarter, 株式会社ＴＧビジネスサービス acquired shares in 株式会社キヅキ, which operates the businesses described above, and the latter was newly included in the scope of consolidation. As a result, as of 30 September 2020, the Group comprised the Company and 14 consolidated subsidiaries.」
Following the acquisition of shares in 株式会社キヅキ by 株式会社ＴＧビジネスサービス, the number of consolidated subsidiaries increased to 14. - FY2021-Q1ReframedAnnual report
「As a result, as of 30 June 2020, the Group comprised the Company and 13 consolidated subsidiaries. Accordingly, the former 3 segments, the CRO, diagnostic analysis and TGBS businesses, were changed to 2 segments: the drug discovery support and TGBS businesses.」
Following 医化学創薬株式会社 becoming a consolidated subsidiary, the number of consolidated subsidiaries rose to 13, and the reportable segments were reorganized into 2 segments by integrating the CRO and diagnostic analysis businesses. - FY2020AdvancedAnnual report
「The Group, comprising the Company, 12 subsidiaries and 1 affiliate, is principally engaged in contract production of genetically modified mice and antibodies, contract clinical and nonclinical studies, contract genetic analysis, pathological diagnostic services, promotion of new businesses through M&A, and advisory and support services in business succession and business revitalization.」
Following the addition of ギャラックス貿易 as a subsidiary, the Group comprised 12 subsidiaries and 1 affiliate, expanding its portfolio centered on the 3 businesses of CRO, diagnostic analysis and TGBS. - FY2020-Q3RestatedAnnual report
「There were no material changes in the principal businesses conducted by the Group, comprising the Company and its affiliates, during the nine-month period ended in the third quarter.」
This reconfirms that there were no material changes to the business portfolio. As of 31 December 2019, the Group comprised 11 consolidated subsidiaries and 1 equity-method affiliate. - FY2020-Q2RestatedAnnual report
「There were no material changes in the principal businesses conducted by the Group, comprising the Company and its affiliates, during the six-month period ended in the second quarter.」
This reconfirms that there were no material changes to the business portfolio centered on the 3 segments of the CRO, diagnostic analysis and TGBS businesses. As of 30 September 2019, the Group comprised 11 consolidated subsidiaries and 1 equity-method affiliate, including ＴＧＭ. - FY2020-Q1AdvancedAnnual report
「During the three-month period ended in the first quarter, 株式会社ＴＧビジネスサービス acquired shares in 株式会社ＴＧＭ, which operates the businesses described above, and the latter was newly included in the scope of consolidation. As a result, as of 30 June 2019, the Group comprised the Company, 11 consolidated subsidiaries and 1 equity-method affiliate.」
Following the acquisition of shares in ＴＧＭ, the company became a consolidated subsidiary from the current quarter, bringing the number of consolidated subsidiaries to 11. - FY2019RestatedAnnual report
「The Group, comprising the Company, 10 subsidiaries and 1 affiliate, is principally engaged in contract production of genetically modified mice and antibodies, contract clinical and nonclinical studies, contract genetic analysis, pathological diagnostic services, promotion of new businesses through M&A, and advisory and support services in business succession and business revitalization.」
This reconfirms the Group structure comprising 3 segments, the CRO, diagnostic analysis and TGBS businesses, and services centered on drug discovery support, diagnostics and M&A. - FY2019-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group, comprising the Company and its affiliated companies, during the third quarter of the current consolidated cumulative period. There were also no changes among the principal affiliated companies.」
This reconfirms that there were no material changes to the business portfolio or the principal affiliates. The reportable segments continue to be presented as 3 segments: the CRO, diagnostic analysis and TGBS businesses. - FY2019-Q2RestatedAnnual report
「From the first quarter of the current fiscal year, the reportable segments have been changed as follows. The former genomics and CRO businesses have been integrated and presented as the CRO business. The former advanced medicine and pathological diagnostics businesses have been integrated and presented as the diagnostic analysis business.」
This restates the 3-segment presentation, with the genomics and CRO businesses integrated into the CRO business and the advanced medicine and pathological diagnostics businesses integrated into the diagnostic analysis business. - FY2019-Q1ReframedAnnual report
「Accordingly, the 5 former segments, namely the genomics, CRO, TGBS, advanced medicine and pathological diagnostics businesses, were changed to 3 segments: the CRO, diagnostic analysis and TGBS businesses.」
The genomics business was integrated into the CRO business, and the advanced medicine business into the pathological diagnostics business, reorganizing the reportable segments from 5 to 3. - FY2018-Q3AdvancedAnnual report
「As a result, as of 31 December 2017, the Group comprised the Company, 7 consolidated subsidiaries and 1 equity-method affiliate.」
With the establishment of ＴＧビジネスサービス and the acquisition of ルーペックスジャパン and its subsidiaries, TGBS was added to the existing 4 businesses, expanding the reportable segments to 5. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies). There were also no changes among its principal affiliated companies.」
It expressly states that there were no material changes to the business portfolio comprising 4 businesses or to the principal affiliates. - FY2018-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group, comprising the Company and its affiliated companies, during the first quarter of the current consolidated cumulative period. There were also no changes among the principal affiliated companies.」
It expressly states that there were no material changes to the business portfolio comprising 4 businesses or to the principal affiliates. - FY2017RestatedAnnual report
「The Group, comprising the Company, 4 subsidiaries and 1 affiliate, is principally engaged in contract production of knockout mice and antibodies, contract clinical and nonclinical studies, contract genetic analysis, and pathological diagnostic services.」
This restates the Group's business portfolio centered on 4 businesses. - FY2017-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses operated by the Group (the Company and its affiliated companies) during the cumulative third quarter of the fiscal year under review.」
It expressly states that there were no material changes to the business portfolio comprising 4 businesses. - FY2017-Q2RestatedAnnual report
「During the first six months of the current fiscal year, there were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies).」
It expressly states that there were no material changes in the business activities, and the portfolio of 4 businesses has been maintained. - FY2016First statedAnnual report
「The principal businesses are contract production of knockout mice and antibodies, contract clinical and nonclinical studies, contract genetic analysis, and pathological diagnostic services.」
The reportable segments comprise 4 businesses: genomics, CRO services, advanced medicine and pathological diagnostics.